Q3 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) reported net product sales of $7.0 million for the third quarter of 2024, an increase from $6.5 million in the same quarter of 2023.
- The company has achieved over 90% reimbursement for Pedmark in the adolescent and young adult (AYA) population, indicating strong market acceptance.
- Fennec Pharmaceuticals Inc (FENC) has strengthened its leadership team with the appointment of experienced executives, which is expected to enhance operational efficiency and strategic execution.
- The company is expanding its market presence with plans to launch Pedmark in Germany and the UK, providing additional revenue streams in 2025.
- Fennec Pharmaceuticals Inc (FENC) has a strong cash position with approximately $40.3 million in cash, cash equivalents, and investment securities, sufficient to fund operations into at least 2026.
- General and administrative expenses increased significantly to $6.1 million in Q3 2024 from $3.8 million in Q3 2023, partly due to non-cash stock compensation and severance payments.
- The company is facing ongoing intellectual property litigation, which could pose financial and operational risks.
- There is an awareness gap among physicians regarding the availability of Pedmark as a preventative treatment, particularly in the AYA market.
- Fennec Pharmaceuticals Inc (FENC) is still working to convert institutions that rely on compounded versions of sodium thiosulfate to adopt Pedmark.
- The market modeling for Fennec Pharmaceuticals Inc (FENC) remains challenging for analysts, indicating uncertainty in near-term revenue projections.
Good morning, ladies and gentlemen and welcome to Fnic Pharmaceuticals third quarter, 2024 earnings and corporate update conference call. At this time, all participants are in listen-only mode later will conduct question and answer session and instructions on how to participate will begin at that time. If any requires operator assistance during today's call, please press star zero on your telephone as a reminder, today's conference call is being recorded. Now, I would like to turn the conference over to fi Chief Financial Officer Robert on Friday.
Thank you operator and good morning everyone. We appreciate you joining us today for Fenwick Pharmaceuticals third quarter, 2024 earnings conference call during which we will review our financial results as well as provide a general business update.
Joining me from Fenwick this morning is our Chief Executive Officer and board member, Jeff Hackman. As a reminder, Jeff joined Fenwick on August 5th and just a few short months has made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
